1. Home
  2. Labeler Index
  3. Cardinal Health 107, Llc
  4. 55154-3367
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Levetiracetam NDC 55154-3367 by Cardinal Health 107, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

bag label - 0348FEC4 D919 4307 AC90 35360819BC00 00

bag label - 0348FEC4 D919 4307 AC90 35360819BC00 00

Levetiracetam Tablets USP is a prescription medication used to treat seizures in adults and children. Each film-coated tablet contains 500 mg of Levetiracetam USP. Dosage recommendations, prescribing information, precautions, and warnings can be found in the product insert. These tablets should be stored at room temperature, and should be kept out of reach of children in a tight, light-resistant container with a child-resistant closure. This particular package is intended for institutional use only and should be dispensed by a pharmacist with a medication guide. The medication is distributed in the United States by Aurobindo Pharma USA, Inc and Major® Pharmaceuticals through Cardinal Health.*

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

The image shows the Responder Rate in Study 2 where the percentage reduction from baseline is 250% during Period A. Three groups are compared, the placebo group with 111 patients, and two groups taking different doses of Levetiracetam (1000 mg/day and 2000 mg/day) with 106 and 105 patients respectively. One group had a statistically significant difference when compared to the placebo group.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

This is a graph depicting the responder rate of participants who experienced a reduction of over 50% in symptoms from their baseline in Study 3. The percentages are displayed on the y-axis, while the different treatment groups are shown on the x-axis. The placebo group had a responder rate of 14.4%, while the group treated with Levetiracetam 3000 mg/day had a responder rate of 45%, which was statistically significant compared to the placebo group.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

The text describes a figure (Figure 4) that shows the Responder Rate in a study (Study 4). The Responder Rate is defined as a 50% reduction from the baseline. The figure shows that the Responder Rate for Levetiracetam (N=101) is statistically significant compared to Placebo (N=97). The Responder Rate for Levetiracetam is 44.6% while for Placebo it is only 19.6%. The figure also displays a graph with percentages ranging from 40% to 30% with both Placebo and Levetiracetam marked on it.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

The figure displays the responder rate for patients aged 1 month to less than 4 years old in Study 5. The rate of reduction from baseline is greater than 50%. The response rate for Lovetracatam (4-58) is statistically significant when compared to the placebo treatment.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

The text describes a Figure 6 that shows the Responder Rate in PGTC Seizure Frequency per Week in Study 7. There is a chart with percentage values from 0% to 100%, where the Levetiracetam group had a responder rate of 72.2% compared to the placebo group which had a responder rate of 45.2%. The chart also notes that the difference between the two groups is statistically significant.*

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.